Review for "The landscape of <i>BCR-ABL</i> mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"

Decision letter for "The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"

10.1002/hon.2721/v1/decision1 ◽

2019 ◽

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Philadelphia Chromosome Positive

Download Full-text

Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Thyroid ◽

10.1089/thy.2010.0251 ◽

2010 ◽

Vol 20 (11) ◽

pp. 1209-1214 ◽

Cited By ~ 43

Author(s):

Theo D. Kim ◽

Michaela Schwarz ◽

Hendrik Nogai ◽

Peggy Grille ◽

Jörg Westermann ◽

...

Keyword(s):

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Myeloid Leukemia ◽

Thyroid Dysfunction ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Philadelphia Chromosome Positive

Download Full-text

Author response for "The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"

10.1002/hon.2721/v2/response1 ◽

2019 ◽

Author(s):

Sheng-Hsuan Chien ◽

Hsueng-Mei Liu ◽

Po-Ming Chen ◽

Po-Shen Ko ◽

Jeong-Shi Lin ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Author Response ◽

Philadelphia Chromosome Positive

Download Full-text

Decision letter for "The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"

10.1002/hon.2721/v2/decision1 ◽

2020 ◽

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Philadelphia Chromosome Positive

Download Full-text

A phase I study of INNO-406 in patients with advanced Philadelphia chromosome-positive (Ph+) leukemias who are resistant or intolerant to imatinib and may have also failed second-generation tyrosine kinase inhibitors

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.7018 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 7018-7018 ◽

Cited By ~ 5

Author(s):

J. Pinilla-Ibarz ◽

H. M. Kantarjian ◽

J. E. Cortes ◽

P. le Coutre ◽

A. Nagler ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitors ◽

Phase I Study ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Philadelphia Chromosome Positive

Download Full-text

The landscape of BCR‐ABL mutations in patients with Philadelphia chromosome‐positive leukaemias in the era of second‐generation tyrosine kinase inhibitors

Hematological Oncology ◽

10.1002/hon.2721 ◽

2020 ◽

Vol 38 (3) ◽

pp. 390-398

Author(s):

Sheng‐Hsuan Chien ◽

Hsueng‐Mei Liu ◽

Po‐Ming Chen ◽

Po‐Shen Ko ◽

Jeong‐Shi Lin ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Philadelphia Chromosome Positive

Download Full-text

Faculty Opinions recommendation of Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718266974.793496733 ◽

2014 ◽

Author(s):

Jan Starý ◽

Michaela Kotrová

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Minimal Residual Disease ◽

Kinase Inhibitors ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Minimal Residual ◽

Philadelphia Chromosome Positive

Download Full-text

Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status

International Journal of Hematology ◽

10.1007/s12185-014-1531-0 ◽

2014 ◽

Vol 99 (4) ◽

pp. 513-518 ◽

Cited By ~ 13

Author(s):

Chika Kawajiri ◽

Hiroaki Tanaka ◽

Shinichiro Hashimoto ◽

Yusuke Takeda ◽

Shio Sakai ◽

...

Keyword(s):

Acute Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Successful Treatment ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Mutation Status ◽

Mixed Phenotype Acute Leukemia ◽

Mixed Phenotype

Download Full-text

TYROSINE KINASE INHIBITORS PLUS HYPER-CVAD FOR THE FRONTLINE TREATMENT OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Hematology Transfusion and Cell Therapy ◽

10.1016/j.htct.2020.10.316 ◽

2020 ◽

Vol 42 ◽

pp. 187-188

Author(s):

R.D. Portugal ◽

M.M. Loureiro ◽

F. Machado ◽

F. Santana ◽

K. Urago ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Frontline Treatment ◽

Philadelphia Chromosome Positive

Download Full-text

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells

Oncotarget ◽

10.18632/oncotarget.10605 ◽

2016 ◽

Vol 7 (33) ◽

pp. 53116-53126 ◽

Cited By ~ 4

Author(s):

Seiichi Okabe ◽

Tetsuzo Tauchi ◽

Yuko Tanaka ◽

Juri Sakuta ◽

Kazuma Ohyashiki

Keyword(s):

Combination Therapy ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Abl Tyrosine Kinase ◽

Philadelphia Chromosome Positive ◽

Resistant Cells

Download Full-text

Review for "The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"

Decision letter for "The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"

Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Author response for "The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"

Decision letter for "The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"

A phase I study of INNO-406 in patients with advanced Philadelphia chromosome-positive (Ph+) leukemias who are resistant or intolerant to imatinib and may have also failed second-generation tyrosine kinase inhibitors

The landscape of BCR‐ABL mutations in patients with Philadelphia chromosome‐positive leukaemias in the era of second‐generation tyrosine kinase inhibitors

Faculty Opinions recommendation of Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.

Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status

TYROSINE KINASE INHIBITORS PLUS HYPER-CVAD FOR THE FRONTLINE TREATMENT OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells

Export Citation Format